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Abstract
Spinal muscular atrophy (SMA) is a severe neuromuscular disease, the most common in in-
fancy, and the third one among young people under 18 years. The major pathological land-
mark of SMA is a selective degeneration of lower motor neurons, resulting in progressive
skeletal muscle denervation, atrophy, and paralysis. Recently, it has been shown that spe-
cific or general changes in the activity of ribonucleoprotein containing micro RNAs (miR-
NAs) play a role in the development of SMA. Additionally miRNA-206 has been shown to be
required for efficient regeneration of neuromuscular synapses after acute nerve injury in an
ALS mouse model. Therefore, we correlated the morphology and the architecture of the
neuromuscular junctions (NMJs) of quadriceps, a muscle affected in the early stage of the
disease, with the expression levels of miRNA-206 in a mouse model of intermediate SMA
(SMAII), one of the most frequently used experimental model. Our results showed a de-
crease in the percentage of type II fibers, an increase in atrophic muscle fibers and a re-
markable accumulation of neurofilament (NF) in the pre-synaptic terminal of the NMJs in the
quadriceps of SMAII mice. Furthermore, molecular investigation showed a direct link be-
tween miRNA-206-HDAC4-FGFBP1, and in particular, a strong up-regulation of this path-
way in the late phase of the disease. We propose that miRNA-206 is activated as survival
endogenous mechanism, although not sufficient to rescue the integrity of motor neurons.
We speculate that early modulation of miRNA-206 expression might delay SMA neurode-
generative pathway and that miRNA-206 could be an innovative, still relatively unexplored,
therapeutic target for SMA.
Introduction
Spinal muscular atrophy (SMA) is a severe neuromuscular disease, the most common in infancy,
and the third one among young people under 18 years. The frequency is 8–11 per 100.000 live
births [1,2], but one person over 35/50 carries its autosomal recessive gene. Clinical features range
from themost severe form (SMAI) to the mildest one (SMAIV), in which patients retain a normal
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life of relation and have a normal life expectancy. The pathological landmark of SMA is the selec-
tive degeneration of lower motor neurons, resulting in progressive skeletal muscle denervation,
atrophy, particularly of the proximal muscles, and paralysis [3]. Moreover, we have recently
demonstrated a selective reduction of layer V pyramidal neurons in the SMAmurine model [4].
The disease is caused by homozygous deletions or mutations in the survival motor neuron
gene, SMN1. In fact, the SMN gene is present in the human genome in two forms, SMN1, the
ancestral telomeric copy, and SMN2, a centromeric paralogue that arose in recent evolution
through duplication [5]. SMA patients lack SMN1, but always carry at least one copy of SMN2
—a complete loss of SMN is incompatible with life. However, SMN2 protein is only partially
functional: a critical, translationally silent single nucleotide C to T transition 6bp inside SMN2
exon7 profoundly influences splicing, therefore, 90% of the protein is unstable and rapidly de-
graded [6,7] and is unable to compensate for the lack of SMN1 [8,9]. The severity of the disease
is inversely proportional to SMN2 copy number [10].
SMN1 encodes a 38-kDa protein, that is expressed in all tissues and localized to the nucleus
and cytoplasm [11] and has its primary and most prominent role in spliceosomal assembly and
pre-mRNAs maturation. How reduced SMN levels lead to selective degeneration of motor neu-
rons in SMA still remains elusive. The key role played by SMN in RNA processing suggests
that splicing defects lead to breakdown of the neuromuscular system [12]. However, splicing
defects occur only during late stages of the disease, and are unlikely to contribute to the patho-
genesis [13]. Alternative hypotheses focused on the role of SMN in transport of mRNA in neu-
rons [11], and on additional neuronal or muscle specific functions [14,15]. Furthermore,
motor neuron subtypes differ strikingly from each other in the extent to which they are affected
by SMA. Usually, the weakness is symmetrical and more proximal than distal. By contrast, sev-
eral subsets are still intact at the disease endpoint [16].
Recently, micro RNA (miRNA) were shown to be a component of a novel class of ribonu-
cleoprotein (RNP) complexes termed miRNPs [17], that contain the proteins Gemin3 [18] (a
putative RNA helicase), Gemin4 [19] (a cofactor of Gemin3) and eIF2C2 [17] (a member of the
argonaute family of proteins). Gemin3 and Gemin4 are also components of the SMN complex,
a large multiprotein complex containing SMN, Gemin2 [20], Gemin5 [21,22], Gemin6 [23,24]
and Gemin7 [25], that functions in the assembly/restructuring of RNPs and transcriptosomes
[26]. Therefore, it is possible that specific or general changes in the activity of the miRNPs, due
to possible redistribution or changes in the levels of Gemin3 and Gemin4, play a role in the de-
velopment of SMA [27]. In particular, mice that do not process miRNA in spinal muscular neu-
rons exhibit hallmarks of SMA and the skeletal muscle-specific (myomiR) miRNA-206, highly
conserved inHomo Sapiens, Rattus norvegicus andMus musculus, was found in the RNPs from
mouse neuronal cells [27,28]. Furthermore, Williams and coll. [29] showed that miRNA-206 is
dramatically induced in a mouse model of amyotrophic lateral sclerosis (ALS), a neurodegener-
ative disease with different etiology, characterized, similarly to SMA, by loss of motor neurons,
denervation, atrophy and paralysis of target muscles [30,31]. In particular, they show that
knocking-out miRNA-206 in the ALS mouse accelerates disease progression, and that miRNA-
206 is required for efficient regeneration of neuromuscular synapses after acute nerve injury, at
least, in part through histone deacetylase 4 (HDAC4) signaling pathways [29]. Interestingly, it
has been recently shown that HDAC4 expression levels negatively correlate with the extent of
muscle re-innervation and functional outcome in patients with ALS [32].
Therefore, seen the tight relationship between SMN and miRNPs complexes, and the neuro-
protective role of miRNA-206 in the regeneration of the neuromuscular junction (NMJ) in
ALS, we investigated the miRNA-206 pathway in a mouse model of intermediate SMA
(SMAII), the SMNΔ7 mice, morphologically and molecularly analyzing the fibers of the quad-
riceps, a muscle affected in the early stage disease [33,34]. This is one of the most common
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SMAmodels: mice have a lifespan of about 2 weeks and impairment of motor behavior clearly
detectable 5–6 days after birth (P5-P6). Different aspects of this model have been analyzed in a
number of studies, and some discrepancies still exist on the number and subgroups of spinal
motor neurons affected during disease progression [35]. Our results showed, in quadriceps of
SMAmice sacrificed at P10, a decrease in the percentage of type II fibers (fast-twitch fatigable
and fast-twitch fatigue resistant); an increase in atrophic muscle fibers and the accumulation of
neurofilament (NF) in the pre-synaptic terminal of the NMJs. Furthermore, molecular investi-
gation suggest a direct link between miRNA-206-HDAC4-FGFBP1, and, in particular, a strong
modulation of this pathway, probably activated as survival endogenous mechanism, although
not sufficient to rescue the integrity of motor neurons. We speculate that modulating miRNA-
206 expression might regulate the neurodegenerative pathway, crucial to motor neuron func-
tion and survival. Therefore, miRNA therapeutics, based on extensive research into specific tar-
get interactions, holds much promise as future therapies for this neurodegenerative disease.
Materials and Methods
Animal Care and Use
All experimental procedures on live animals were performed in strict accordance to the Euro-
pean Communities Council Directive 86/609/EEC (November 24, 1986) Italian Ministry of
Health and University of Turin institutional guidelines on animal welfare (law 116/92 on Care
and Protection of living animals undergoing experimental or other scientific procedures; au-
thorization number 17/2010-B, June 30, 2010): additionally an ad hoc Ethical Committee of
the University of Turin specifically approved this study. All efforts were made to minimize the
number of animals used and their suffering.
The original breeding pairs of SMNΔ7 mice were purchased from Jackson Laboratory
(stock number 005025; Jackson Laboratories). They were originally generated in the laboratory
of A. Burghes [36] and are homozygous for both transgenes (hsmn2 and smnΔ7) that allow
mice that are homozygous null for mouse smn, and would otherwise die embryonically, to sur-
vive to the end of the second postnatal week. To maintain the colony required the identification
of mice heterozygous for deletion of smn (smn+/-, carrier), that are fully viable, and their inter-
breeding. Mice afflicted with SMA are the homozygous mutant for smn: smn-/-. The offspring
were genotyped by PCR assays. Mice had free access to food and water. Data were obtained
from knock-out SMA (smn-/-, SMA) and wild type (smn+/+, WT) mice sacrificed at P5 and
P10, P11 and P12 (P10/12), considering P0 as the day of birth.
Genotyping mice
DNA from mouse tail was extracted incubating a small piece of tail in 100μl of lysis buffer
(10mM Tris HCl, 50mM KCl, 0.01% gelatin, 0.45% IGEPAL, 0.4% Tween-20) and 25μg of pro-
teinase k at 55°C over night under gentle shaking [37]. The absence of the survival motor neu-
ron gene (smn) was determined by PCR analysis using primers that amplify a portion of the
smn gene, yielding a 420 bp product for the wild type (WT) allele and a 150 bp product for the
knocked-out one (SMA). They were: smn fwd 5’-TTTTCTCCCTCTTCAGAGTGAT-3’, smn
wt rev 5’-CTGTTTCAAGGGAGTTGTGGC-3’ and smn tg rev 5’-GGTAACGCCAGGGTTTT
CC-3’ as suggested by supplier’s (Jackson Laboratories).
Quadriceps histological examination
P10 mice (WT n = 17; SMA n = 10) were deeply anesthetized by gaseous anesthesia (3% iso-
flurane vaporized in O2/N2O 50:50) and perfused transcardially with 4% buffered
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paraformaldehyde (PFA, pH 7.4). Quadriceps were collected and postfixed in 4% PFA for 2
hours at 4°C. Samples were then transferred overnight into 30% sucrose in phosphate buffer
(PB) 0.1M at 4°C for cryoprotection, embedded in cryostat medium (Killik) and cut on the
cryostat (HM 550; Microm). Then, muscles underwent different histological procedures.
Hematoxylin/eosin staining. In order to morphologically evaluate the muscle (in terms of
mean fiber area, quadriceps cross-sectional area, mean muscular fiber number), the quadriceps
(WT n = 6; SMA n = 5) were cut on the cryostat in transverse 20μm thick sections, mounted di-
rectly onto 5% gelatin-coated slides, stained with hematoxylin/eosin, dehydrated in ascending
series of ethanol (95–100%) and cleared in xylene. The sections were drawn and analysed by
Neurolucida software (MicroBrightField Inc., VT) and data were obtained by the associated
data analysis software NeuroExplorer (MicroBrightField).
Cytochrome c Oxidase (COX) assay. To assess fiber type composition, the samples (WT
n = 5; SMA n = 3) were cut on the cryostat in transverse 50μm-thick sections free-floating in
phosphate-buffered saline (PBS) and directly processed for the COX histochemistry. The reac-
tion solution contained 10ml PBS 0.1M, 0.4g sucrose, 10mg DAB and 5mg cytochrome C
(Sigma Aldrich). The solution was heated at 37°C before incubating the sections. Quadriceps
were incubated with the reaction solution for 2–3 hours at 37°C on a tilting plate. We classified
the fibers in the COX-stained muscle sections as follows: the dark ones were identified as oxi-
dative fibers (type I), whereas light ones as glycolytic fibers (type II) [38].
Immunofluorescence. The samples (WT n = 5; SMA n = 7) were cut in longitudinal 20μm-
thick sections mounted directly onto 5% gelatin-coated slides, immunoreacted and used to assess
the NMJ innervation/denervation. Briefly, the tissue was permeabilized for 20 min in PBS-Triton
0.3% at RT on a tilting plate and then incubated with Alexafluor 555-conjugated α-Bungarotoxin
(BTX) (1:500; Invitrogen) at RT for 30 min. After blocking non-specific binding sites for 30 min
at RT with 0.3% Triton X-100 and 10% normal donkey serum (Sigma-Aldrich) in PBS 1X (pH
7.4), the sections were incubated with the monoclonal antibody anti-neurofilament 165 kDa
(2H3 clone; mouse; 1:500; Hybridoma bank) in the same solution at 4°C overnight. After being
washed in PBS 1X, the sections were incubated with secondary antibody Alexa488 (anti-mouse
1:200; Jackson Immunoresearch) followed by 4’,6 Diamino-2 phenyindole Dilactate (DAPI;
Sigma Aldrich) in PBS 1:50 for 3 min. Samples were washed and coverslips were mounted with a
drop of PB 0.1M with glycerol. The slices were analysed with a Nikon Eclipse 90i epifluorescence
microscope and photographed by a Nikon DS-5Mc digital camera. In order to analyze the inner-
vation, we evaluated the number of NF-positive nerves reaching each endplate at high magnifica-
tion (100x objective): for each sample, about 100 NMJs were randomly evaluated [39]. We
classified them as denervated, mono-innervated or multi-innervated. Moreover, for checking
double staining and making 3D reconstructions, some preparations were examined also with a
Leica TCS SP5 confocal laser scanning microscope. Additionally, some images were also ana-
lyzed using the isosurface module of Imaris software (Bitplane). Finally, we studied the endplate
area and the NMJ density inWT and SMAmice (WT n = 3; SMA n = 3): all the BTX-positive
endplates present in 20μm-thick longitudinal quadriceps sections were analyzed and drawn by
Neurolucida software (MicroBrightField Inc., VT). Mean NMJ areas were calculated for both
groups, and size distribution histograms (expressed in percentage) were constructed by grouping
cross-sectional areas in 10μm2 bins. NMJ density has been expressed as a percentage of the end-
plate area covered on the total quadriceps area.
Transfection
The myoblast cell line C2C12 (ATCC) was grown in RPMI supplemented with 10% FBS, peni-
cillin (100units/ml) and streptomycin (100μg/ml) (Life Technologies). C2C12 cells were seeded
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at a density of 4x104 (30% confluence) and 8x104 (60% confluence) on 12-mm diameter plastic
dishes and maintained at 37°C in a humified 5% CO2/95% air atmosphere. Twenty-four hours
after seeding, they were transfected with 40pmols of miRNA-206/non targeting control
miRNA (NT-miRNA, Bioneer) with lipofectamine 2000 following supplier’s instructions (Life
Technologies). After a 4 hours incubation period, the medium was replaced with a fresh one.
Forty-eight hours after transfection cells were collected for RT-PCR and WB analysis.
RT-PCR analysis
C2C12 cells transfected with miRNA-206/NT-miRNA were collected in Trizol and total RNA
was extracted following supplier’s instructions (Life Technologies). Quadriceps were quickly
removed from P5 and P10, P11 and P12 mice after decapitation, then immediately frozen on
dry ice and stored at -80°C until use (WT n = 14; SMA n = 15). Mice tissues were homogenated
in liquid nitrogen and total RNA, enriched in miRNAs, was extracted with MirVana extraction
Kit following supplier’s instructions (Life Technologies). The first-strand cDNA was synthe-
sized with 0.5μg or 2μg of total RNA using the High Capacity cDNA Reverse Transcription Kit
following supplier’s instruction (Life Technologies). Quantitative real-time PCR was per-
formed with SYBR green core reagent kit for pri-miRNA-206 or TaqMan assays for mature
miRNA-206 and FGFBP1 in a StepOne real time PCR system (Life Technologies). The primers
used for pri-miRNA-206 were 5’-GTGTGTGGTTTTGGCAAGTG-3’ and 5’-GGGAGCATA
GTTGACCTGAAA-3’ [29]; and for the Rpl26, used as housekeeping gene for data normaliza-
tion, were 5’-CGAGTCCAGCGAGAGAAGG-3’ and 5’-GCAGTCTTTAATGAAAGCCGTG-3’
[40]. Samples were amplified simultaneously in triplicate in 1 assay run. Changes in mRNA
levels were determined as the difference in threshold cycle (ΔCt) between the target gene and
the reference gene.
We considered as a single group P10, P11 and P12 mice (P10/12), since we did not observed
differences in terms of molecular expression of the gene analyzed. On the contrary, for P5
group of animals we used only muscles from pups sacrificed exactly five days after birth, seen
that the change in miRNA-206 expression pathway observed arose in the time lapse between
five and ten days after birth.
Western blot
Total extract proteins were prepared from transfected C2C12 cells and from quadriceps homo-
genated in liquid nitrogen (WT n = 8; SMA n = 8). They were resuspended in ice-cold lysis
buffer (20mMHepes pH 7.5, 1%Triton, 150mMNaCl, 10mM NaF, 1mMNa3VO4, 0.5μg/ml
apronitin, 1μg/ml leupeptin, 1μg/ml pepstatin) and then cleared by centrifugation. The super-
natant was used for Western blot analysis after protein determination by the Bio-Rad protein
assay (Biorad). Samples with equal protein concentration were resolved by SDS-PAGE on
4–12% NUPAGE gels using MES running buffer (Life Technologies) and subsequently blotted
to nitrocellulose membrane (Amersham) To detect the proteins of interest, specific antibodies:
anti-HDAC4 (rabbit polyclonal antibody, 1:500, Santa Cruz Biotechnology) and anti-GAPDH
(mouse monoclonal, 1:1000, Millipore) were used. Immunoreaction was revealed using anti-
mouse and anti-rabbit IgG conjugated to peroxidase, 1:2000 (Ge Healthcare) by the ECL re-
agent (Ge Healthcare). The optical density of the bands was determined by Chemi Doc Imag-
ing System (Biorad) and normalized to the optical density of GAPDH.
Statistical analysis
The data were evaluated as means ± standard error of mean (SEM). All data were expressed as
absolute value, except the fiber type composition following COX histochemistry, the
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classification of NMJ innervation and the NMJ density, that were expressed as a percentage.
For in vivo gene expression analysis, statistically significant differences among means were de-
termined by ANOVA followed by post hoc Newman-Keuls test. For two experimental groups
analysis (SMA vs WT), statistically significant differences among means were determined by t-
test. The threshold for statistical significance data was set at p<0.05. Statistical analysis was
performed using GraphPad Prism 6.0 software (GraphPad Software).
Results
Morphological analysis of quadriceps
We analyzed the morphology of quadriceps muscles, in WT and SMAmice at P10 by Cytor-
ome c Oxidase (COX) histochemistry, hematoxylin/eosin staining (Fig 1), and the innervations
of the NMJs by α-bungarotoxin and NF immunoreactions (Fig 2).
The COX reaction highlighted the mitochondrial activity of the different types of muscle fi-
bers, therefore, we could classify them (Fig 1A and 1B). Our results showed a significant change
in the fiber type distribution: type I fibers in WT mice were 82.00 ± 1.82% and in SMAmice
88.33 ± 0.33%). Consequently type II fibers were 18.00 ± 1.82% in WT and 11.67 ± 0.33% in
SMAmice (Fig 1E).
After hematoxylin/eosin staining (Fig 1C and 1D), we analyzed the morphology of the mus-
cle samples by Neurolucida software. We evaluated the mean fiber area, the mean number of
muscle fibers and the overall quadriceps cross-sectional area in WT and SMAmice. We ob-
served a statistically significant difference in the mean fiber area: WT 146.40 ± 2.35 μm2 vs
SMA 127.39 ± 2.09 μm2 (Fig 1F). The other parameters showed a reduction trend in SMA com-
pared to WT mice, but they did not show statistically significant differences. In particular, the
mean number of muscle fibers was 8521.12 ± 514.59 in WT vs 7206.65 ± 1361.71 in SMAmice
(Fig 1G), whereas the quadriceps total area was 3.21 ± 0.43 x106 μm2 in WT vs 2.59 ± 0.26 x106
μm2 in SMAmice (Fig 1H). Finally we checked the nuclei position into the SMA quadriceps
and we did not observed centrally-nucleated fibers.
Furthermore, the analysis of the NMJ revealed dramatic abnormalities in the NMJs of SMA
(Fig 2). Indeed, we observed altered NMJs, characterized by an aberrant NF accumulation (Fig
2A and 2C). We also observed that SMA NMJ postsynaptic terminals were simplified, with a
decreased number of perforations compared to WT (Fig 2D and 2E). Rare endplates in SMA
quadriceps also presented fragmentation (Fig 2F). Additionally, we classified the fibers accord-
ing to their innervation: WT mice showed 2.75 ± 1.25% denervated fibers, 84.25 ± 2.39%
mono-innervated fibers and 13.25 ± 2.14% multi-innervated fibers, compared to SMA mice
5.71 ± 2.22%, 80.29 ± 3.35% and 14.14 ± 3.38%, respectively (Fig 2G).
Finally, by Neurolucida software analysis, we compared NMJ area of WT and SMA mice.
The analysis of the distribution of NMJ areas (bins = 10 μm) showed a dramatic shift to lower
endplate size in SMA compared to WTmice (Fig 2H). In fact, the mean NMJ area was signifi-
cantly smaller in WT mice compared to SMA quadriceps (87.21 ± 10.79 μm2 vs
53.58 ± 4.31 μm2, respectively; Fig 2I), while the NMJ density, expressed as a percentage of the
endplate area covered on the total quadriceps area, did not differ significantly (0.182 ± 0.025%
in WT vs 0.122 ± 0.007 in SMAmice).
Molecular investigation of miRNA-206 pathway in vitro and in vivo
For molecular investigation, first of all we confirmed the existence of a miRNA-
206-HDAC4-FGFBP1 pathway in C2C12 cell lines. In particular, we transiently transfected a
miRNA-206 mimic and a non targeting miRNA as negative control (NT miRNA), in C2C12 at
two different confluences, 30% and 60%. Forty-eight hours after transfection, cells were
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harvested and HDAC4 protein and FGFBP1 mRNA levels were measured by WB and real time
PCR, respectively. Our results showed, in both experimental conditions, a down-regulation of
HDAC4 (Fig 3A and 3B), as expected for a miRNA target, and a parallel strong up-regulation
of FGFBP1 mRNA (Fig 3C), as a consequence of the miRNA mediated down-regulation of
HDAC4 inhibitory effect on FGFBP1. Therefore, we could assume a direct link between
miRNA-206, HDAC4 and FGFBP1 and decided to investigate the modulation of this molecular
pathway in SMA quadriceps.
The molecular events leading to muscle fibers and NMJs alterations observed at P10 by
morphological analyses might have taken place early in advance. Therefore, seen the overall
differences in quadriceps of SMAmice at P10, we analyzed the expression levels of pri-
miRNA-206 and mature miRNA-206 in a early stage of the disease (P5) and in an advanced
stage of the disease (P10/12) by real time PCR in the quadriceps of both WT and SMAmice.
Our results showed a strong up-regulation of both pri-miRNA-206 (2.5-fold increase) and
miRNA-206 (5.6-fold increase) in SMA compared to WTmice only at P10/12 (Fig 4A and 4B).
In particular, the physiological reduction in mature miRNA-206 occurring after birth in WT
mice did not occur in SMAmice. Furthermore, the HDAC4 protein showed a significant
down-regulation in the quadriceps of SMA mice at P10/12 and not a P5 (Fig 4C). Accordingly,
Fig 1. Fiber morphology of the quadriceps inWT and SMAmice at P10. Panels A-B, Cox immunoreaction
on quadriceps of WT (panel A) and SMA (panel B) mice, revealing the mitochondrial activity and the fiber
types. Scale bar = 40μm. Panels C-D showed the samemuscles (WT: panel C; SMA: panel D) stained by
hematoxylin/eosin. Scale bar = 80μm. Panel E, quantification of fiber type I and II in quadriceps of WT and
SMAmice, expressed as percentage of the total number of fibers. Panels F-H, respectively single fiber area,
number of fibers and total area of quadriceps inWT and SMAmice. *p<0.05; ***p<0.001 by t-test analysis.
doi:10.1371/journal.pone.0128560.g001
MiRNA 206 and SMA
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the FGFBP1 mRNA was up-regulated in SMA mice (3-fold increase) only at P10/12, and the
physiological decrease observed in WTmice from P5 to P10/12 did not occur in SMA, in agree-
ment with miRNA-206 modulation (Fig 4D). On the other hand, in the gastrocnemius, we did
not observe differences in miRNA-206 mRNA levels in SMA vs WTmice, excepted for the
physiological down-regulation of miRNA-206 in SMA as well as in WT mice from P5 to P10/
12 (data not shown).
Discussion
Quadriceps histological examination
In the present paper, we correlated morphological and molecular aspects of quadriceps, a mus-
cle rich of slow-twich fibers (type I), in a mouse intermediate model of SMA, the SMNΔ7
mouse (SMA type II). Different aspects of this model have been analyzed but discrepancies re-
garding the NMJ architecture, the composition of the fibers, the extent of neuron loss and de-
nervation still exist [39,41,42]. Our results, by COX histochemistry experiments, showed
Fig 2. Architecture of the NMJ of the quadriceps in WT and SMAmice at P10. Panels A-B,
Immunoreactions for α-bungarotoxin (red) and neurofilament (green) proteins in NMJs of quadriceps of WT
(panel A) and SMA (panel B) mice. Inset C, isosurface module of Imaris software. Nuclei were labeled in blue
with DAPI. The arrow in A points aWT NMJ correctly innervated, whereas arrowheads in B show the
abnormal accumulations of neurofilament in SMA. Scale bar = 10μm. Panels D-F, morphology of NMJs at
higher magnification: WTmice display endplates with a more mature morphology (panel D), compared to
SMA ones (panel E). Additionally rare SMA NMJs appear fragmented, as indicated by arrowhead (panel F).
Scale bar = 10μm. Panel G, quantification of multi-innervated, mono-innervated and denervated endplates in
quadriceps of WT and SMAmice. Panel H, distribution of NMJ area in WT (continuous line) and SMA
(dashed line) endplates expressed as percentage of total number of plaques. Panel I, mean value of NMJ
area in WT and SMA quadriceps. *p<0.05 by t-test analysis.
doi:10.1371/journal.pone.0128560.g002
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significant changes in the fiber type distribution in quadriceps sections of SMAmice sacrificed
at P10. Although skeletal muscle fiber type distribution is quite heterogeneous, the high pro-
portion of type I fibers in the quadriceps is probably due to the fact that these are postural and
locomotive muscles that are active for a long duration, but at low contractile forces [43,44]. In
particular, we found a 33% decrease in type II fibers (fast), and a parallel increase in type I fi-
bers (slow) compared to age-matched WT mice, suggesting that slow motor units of the quad-
riceps are more resistant. These results are in agreement with studies of Dubowitz [45]
conducted on muscle biopsies from severe SMA patients, showing widespread atrophy of type
II (fast) fibers and a compensatory hypertrophic effect of type I (slow) fibers. Furthermore, sev-
eral mouse model studies have concluded that fast fatigable motor units are intrinsically more
vulnerable in ALS [46,47]. On the other hand, studies of Murray in SMAI (the most severe
form of SMA) and SMAII mice revealed that motor neurons innervating the transverses abdo-
minis (TVA), a predominantly slow twitch muscle, are more susceptible compared to the leva-
tor auris longus (LAL) and lumbrical muscles, exclusively fast-twich muscles [41]. In addition,
motor neurons innervating the caudal band of the LAL are more susceptible than those inner-
vating the rostral band, suggesting that motor neurons within a single homogeneous muscle, in
terms of muscle fibers composition, can be differentially vulnerable. Therefore, Murray classi-
fied motor neurons according to their FaSyn/DeSyn characteristics, according to the initial
focal clustering of postsynaptic AchRs, the timing of pre-synaptic maturation, and the mainte-
nance of the NMJ in the adult mice [48], suggesting that FaSyn motor units are more vulnera-
ble [41]. In addition, studies of Ling [39] on SMAII mice revealed that many but not all
vulnerable muscle are predominantly fast-twitch, and that several FaSyn muscles are resistant
to denervation, indicating that both classification, according to muscle fiber type or synapsing
phenotype, cannot be the only determinants of NMJ vulnerability. In conclusion, differences in
vulnerability based on motor neuron properties and muscle fiber type exist as our and others
Fig 3. HDAC4 and FGFBP1 expression levels in C2C12 cells transiently transfected with miRNA-206.
Panels A-B, representative Western blots displaying HDAC4 protein levels in C2C12 cells transfected at 30%
confluence (panel A) and at 60% confluence (panel B) with a mimic miRNA-206 (miRNA-206) and with a non
targeting miRNA (NT miRNA) used as control. Graphs below each image report the quantification of HDAC4/
GAPDH protein levels. Panel C, evaluation of FGFBP1mRNA levels in C2C12 cells transfected at 30% and
60% confluence with miRNA-206 and NTmiRNA. *p<0.05 vs respective control by t-test analysis.
doi:10.1371/journal.pone.0128560.g003
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studies showed, although these parameters are not the only ones to be considered to predict
motor neuron vulnerability.
Next, by hematoxylin/eosin staining, we observed a significant 15% reduction in the area of
the single muscle fibers in agreement with previous results. In particular, Lee and coll. [49] re-
ported in the same animal model a severe and uniform reduction in the size of sternomastoid,
extensor digitorum longus and soleus muscles. According to that, muscle shrinkage was also
observed in the transversus abdominis at P7, with a higher degree at P14, in the levator auris
longus muscles at P14 [41] and in the tibialis anterior at P9, reaching higher levels at P13 [42].
Therefore, in an advanced phase of the disease, muscle shrinkage seems to be a widespread
event in SMA fibers [50,51], responsible for the profound muscle weakness observed in SMA
mice. In fact, the myofiber contractile strength is determined by its diameter [52] and by the
composition of myosin heavy chains [53]. Finally, we checked the presence of centrally nucle-
ated fibers, since this is considered a common pathological feature in a number of myopathies
(as myotonic dystrophy and limb-girdle muscular dystrophies), but we did not detected myofi-
bers with centralized nuclei. Indeed, such phenomenon is a very rare event in this SMA model,
as confirmed by Avila’s group, that has conversely used this parameter as a sign of regenera-
tion, to be checked after a treatment [54].
Fig 4. pri-miRNA-206, maturemiRNA-206, HDAC4 and FGFBP1 expression levels in quadriceps of WT and SMAmice at P5 and P10/P12. Panels A,
B,D, evaluation of pri-miRNA-206 (panel A), mature miRNA-206 (panel B) and FGFBP1 (panel D) mRNA levels in WT and SMAmice, five (P5) and ten (P10/
12) days after birth. #p<0.05 vs P10/12WT, § p<0.05 vs all group by ANOVA followed by post hoc Newman-Keuls test. Panels C, representative Western
blots displaying HDAC4 protein levels in WT and SMAmice, at P5 (left blot) and P10 (right blot). Graphs below each image report the quantification of
HDAC4/GAPDH protein levels. *p<0.05 vs WT by t-test analysis.
doi:10.1371/journal.pone.0128560.g004
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Quadriceps immunohystochemical examination
Finally, by immunohystochemistry analysis we revealed a deep alteration of the NMJs, in terms
of neurofilament accumulation and endplate area, but we did not observe a significant degree
of denervation of the synaptic terminals. In agreement with our results, NF accumulation was
also observed in the transversus abdominis and in the levator auris longus muscles of SMNΔ7
mice at P7 [41], in the flexor digitorum brevis 2 and 4 already at P1 [39], and in the extensor
digitorum longus, the gastrocnemius, the tibialis anterior and the sternomastoid muscles at
P15 in a different SMNΔ7 mouse model, where the mutation is restricted to neurons, that has a
lifespan of 30 days [3]. Therefore, NF accumulation at the pre-synaptic terminal of the NMJ, a
morphological hallmark of SMA, probably represents an early event in the pathogenesis. Nev-
ertheless, NF accumulation did not seem to correlate with NMJ denervation. In fact, we did not
observe significant differences in the number of denervated, mono-innervated, and multi-in-
nervated plaques in SMA compared to WTmice at P10, in agreement with the minimal dener-
vation observed in the quadriceps of SMAmice at P13 by Kong and coll. [42], and the recent
studies of Ling and coll. [39]. Indeed, Ling found denervation in the majority of the NMJs of
axial muscles investigated and in few appendicular muscles, but not in the quadriceps of end-
stage SMAmice.
Furthermore, our data showed that NMJs of SMA quadriceps were significantly smaller and
immature compared to WT, while the overall density of plaques did not significantly differ.
Our results are in agreement with previous works demonstrating that SMA nerve terminals of
the sternomaistoid at P15 and the tibialis anterior at P5, P9 and P13 are smaller and immature
[42,49]. In fact, postsynaptic AChR aggregates initially appear as simple plaques and then be-
come more complex as perforated plaques, and eventually mature with pretzel-like morpholo-
gy [55]. Our results showed that in the quadriceps of SMA mice, this differentiation is
incomplete, with less perforations and also fragmentation in some endplates. In particular, syn-
aptic dysfunction, due to a decreased density of synaptic vesicles released at motor nerve termi-
nals, results in reduced quantal content of neurotransmission [42,56,57]. These features are
consistent with an abnormally persistent expression of embryonic type of AChRs (γ/fetal vs ε/
adult subunit of AChR) at SMA NMJs that precedes axonal degeneration [42,49]. We did not
detect significant differences in the density of NMJs, probably because to a reduced size of end-
plates area corresponds a smaller total area of quadriceps in SMA mice.
Overall, our studies confirmed and provided novel information on the deep morphological
alterations of SMA quadriceps.
Investigation of miRNA-206 pathway
We investigated the molecular pathway of miRNA-206 in the quadriceps, since its role
emerged in ALS disease [29]. SMA and ALS have very different etiology, but are both charac-
terized by progressive paralysis due to selective death of lower [58] and upper motoneurons
[4]. Furthermore, among the miRNAs that are predominantly expressed in skeletal muscle,
miRNA-206 has been defined as a key promoter of myogenic commitment [59,60]. Its expres-
sion is induced by MyoD, a critical transcriptional factor for muscle differentiation [61]. Aug-
menting the pro-myogenic effect of miRNA-206 has been considered as a therapeutic strategy
to delay not only ALS [29], but also rhabdomyosarcoma [62] and muscular dystrophies
[63,64,65]. Our results showed a miRNA-206 up-regulation in SMA quadriceps at P10/12, in
an advanced stage of the pathology, while at P5, an early phase, we did not observe differences
in miRNA-206 levels compared to WT muscles. Furthermore, in the gastrocnemius, a distal
muscle affected later during pathology [50], we did not observe a miRNA-206 up-regulation,
but on the contrary the physiological decrease observed after birth in WT mice. In fact,
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previous studies showed that, during embryonic development in the mouse, miRNA-206 is
first detected at a very low level as early as E9.5 and thereafter begins to significantly increase
[66]. Post-natal expression of miRNA-206 appears to peak at three days after birth, then it de-
clines [60]. Down-regulation of HDAC4 protein levels have also been observed in SMA quadri-
ceps at P10/12 compared to age matched WTmice. In fact, HDAC4 is a miRNA-206 target
[29,67], as predicted by computational analysis [68,69]. Furthermore, Williams and coll. [29]
show that FGFBP1 was down-regulated in miRNA-206 knock-out mice and up-regulated in
HDAC4 knock-out mice, suggesting a strict correlation between miRNA206-HDAC4 and
FGFBP1; our results confirmed a miRNA-206-HDAC4-FGFBP1 axis in the same in vitro
model. In fact, over-expression of miRNA-206 in C2C12 cells by miRNA mimic transfection
strategy, clearly showed a decrease in HDAC4 protein levels and resulted in FGFBP1 transcrip-
tional up-regulation, as expected following down-regulation of HDAC4 inhibitory effect on
FGFBP1 mRNA.
Role of HDAC inhibitors and FGFs in SMA
HDAC4 is a class II histone deacetylase, highly expressed in striated muscle [70], implicated in
the regulation of cardiac and skeletal muscle growth [71]. Interestingly, inhibitors of HDACs,
such as suberoylanilide hydroxamic acid (SAHA) [72], trichostatin A (TSA) [54], phenylbuty-
rate [73], sodium butyrate [74], valproic acid [75], and hydroxyurea increase SMN2 full length
transcript and have been demonstrated to ameliorate SMA phenotype at least in mouse models
[76,77]. HDAC4 has been well characterized for its ability to repress the myogenic transcrip-
tion factor Mef-2 [78], inducemyogenin expression through the repression of Dach2 gene, a
repressor ofmyogenin [79,80]. In particular, up-regulation of HDAC4 protein by down-regula-
tion of miRNA-206 expression, promotes hypertrophy of cultured myotubes [81]. On the
other hand, over-expression of miRNA-206 in vitro and in vivo, did not result in muscle atro-
phy. Hence, miRNA-206-HDAC4 axis did not alter skeletal muscle mass of young adult mice
[81]. Therefore, we speculated, consistent with Williams’ hypothesis [29], that FGFBP1 is the
key protein downstream HDAC4, responsible of miRNA-206 neuroprotective actions. In fact,
FGFBP1 interacts with FGF-7, FGF-10 and FGF-22 family members and potentiates their bio-
activity by releasing them into the extracellular matrix [82]. FGFs are muscle-derived regula-
tors that promote presynaptic differentiation of the NMJ [83]. For this reason, we speculate
that endogenous miRNA-206 up-regulation, with consequent HDAC4 protein reduction and
FGFBP1 mRNA increase might be a neuroprotective mechanism activated by muscle cells to
increase re-innervation of muscle endplates, however not sufficient, to rescue motor neuron
from death. The late activation of this neuroprotective mechanism might be correlated to the
late denervation of the NMJs. On the contrary, to treat animals in the very early stage disease
would very important for therapeutic efficacy. Indeed, previous studies with self-complementa-
ry adeno-associated virus 9 to delivery SMN (scAAV9-SMN) in SMA pups, demonstrated that
injection of scAAV9-SMN at P1 rescues motor function, neuromuscular physiology and in-
creases lifespan of mice; at P5 results in partial correction; at P10 the treatment has little effect
[84]. According to this study, TSA administration at P5, but not at P10, increases SMN and
SMNΔ7 proteins [54].
Future perspectives in SMA therapy
We speculate that increasing miRNA-206 levels in quadriceps muscles, in a pre-symptomatic
phase of the pathology, can protect motor neurons, improve motor ability and life expectancy
of transgenic mice, similar to the neuroprotective effect observed in ALS mice [29]. Therefore,
further studies are necessary to unravel this important aspect. Indeed, future experiments will
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be drawn to up-regulate miRNA-206 levels in muscles of SMAmice to investigate its neuropro-
tective role and to characterize the complete molecular pathway downstream miRNA-206 acti-
vation. A list of putative miRNA-206 target genes compiled from TargetScan, PicTar and
Miranda databases revealed an over-representation of genes associated with protein modifica-
tion, transport, cytoskeleton organization, RNA metabolism and transcription [69]. However,
further studies are required to investigate other molecular targets of miRNA-206 that could be
relevant in motor neuron diseases. In fact, any given miRNA may have hundreds of targets,
therefore altering the cellular level of a single miRNA has the potential to regulate multiple cel-
lular pathways simultaneously. This property can be advantageous as a means to modulate a
disease process in its entirety. In particular, miRNA therapeutics for neurodegenerative dis-
eases represent a growing field of research as a therapeutic approach. The first miRNA-targeted
drug that enters phase II clinical trials is miravirsen, that specifically binds to miRNA-122 and
effectively decreased hepatitis C virus replication [85]. The mimic of miRNA-34a, a tumor sup-
pressor miRNA, entered phase I clinical trials [86]. Many more miRNA therapeutics are ex-
pected to enter clinical trials as new disease targets are identified and new sequences show
activity in diseases.
Conclusions
Overall, our morphological data confirmed muscle shrinkage in SMA fibers and profound al-
terations of the NMJ, not correlated with denervation of the synaptic terminals; and provided
novel information regarding the fiber type distribution in quadriceps of SMAII mice at P10.
Furthermore, our molecular investigation confirmed a direct link between miRNA-
206-HDAC4 and FGFBP1 in vitro and in vivo, and that this pathway is up-regulated in a late
phase of the disease, suggesting that miRNA-206 could be an innovative, still relatively unex-
plored, strategy to treat SMA. Future studies will be aimed at specifically addressing
these questions.
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